RIDGEFIELD, Conn., Feb.

A new drug combination may keep grafts working better for dialysis patients and boost their chances at a healthier life.

An analysis of previous studies indicates that among patients with peripheral artery disease, aspirin use is associated with a statistically nonsignificant decrease in the risk of a group of combined cardiovascular events

CombinatoRx, Incorporated (NASDAQ: CRXX), today provided in-depth analysis from COMET-1 (CRx-102 Osteoarthritis Multi-center Evaluation Trial), the Company's Phase 2b clinical trial designed to evaluate the safety and efficacy of Synavive(TM) (CRx-102) in subjects with symptomatic knee osteoarthritis (OA).

Researchers are beginning to question if using a blood pressure medicine along with a widely used blood thinner does in fact benefit patients.